A closer look at the coverage of the AlphaFold Human Proteome
In this post of our AlphaFold Series, we look at the gaps in proteome coverage addressed by...
From molecule to medicine
AlphaFold 2: What No One Is Talking About
In this next installment of our AlphaFold Series, we look at the potential drawbacks and...
Building Good Partnerships
At my job, I was frequently asked by external parties what I meant by saying, “Cyclica is a drug...
Cyclica successfully integrates DeepMind’s AlphaFold 2
AlphaFold 2 has provided structures for a large percentage of the proteome, perfectly complementary...
Machine Learning - Groups are collections of similar individuals
Did you notice in a conference room or event, people are grouped based on their similarities? They...
Full Speed Ahead: What DeepMind’s Newest Revelation means for Scientific/Research Advancement
Last Week, DeepMind announced on their blog that they had made available, in collaboration with...
Machine Learning - Less is enough
We don’t need to know everything for decision-making. When doctors assess if a patient is obese or...
Drug Repurposing for COVID19: What has been done, and how we're tackling it.
Originally published on LinkedIn: https://bit.ly/3EqDDeN
Over the past few weeks, we’ve strategized...
Machine Learning: Learning beyond living things
Industrial revolutions throughout history can be defined as pivotal stages in an advancing society,...